Results 111 to 120 of about 32,786 (220)
Biology of Blood and Marrow Transplantation, 2018 With the availability of immunomodulatory imide drugs (IMiDs) and proteasome inhibitors (PI), most patients with immunoglobulin light chain amyloidosis (AL) receive induction therapy before autologous hematopoietic stem cell transplantation (auto-HCT ...
A. Afrough +16 more
semanticscholar +1 more source
eJHaem, Volume 7, Issue 3, June 2026.ABSTRACT Introduction Light chain (AL) amyloidosis and transthyretin amyloid cardiomyopathy (ATTR‐CM) are the most common types of cardiac amyloidosis. Despite similar manifestations, prognosis and treatments are distinct, emphasizing the importance of accurate and timely diagnosis. This retrospective cohort study assessed real‐world diagnostic workups
Muhamed Baljevic +7 more
wiley +1 more source
Liver International Communications, Volume 7, Issue 2, June 2026.ABSTRACT Monoclonal immunoglobulin deposition disease (MIDD) is a plasma cell disorder where immunoglobulin light‐ and/or heavy‐chains accumulate in various organs. Hepatic involvement can be challenging to diagnose, as manifestations are protean and Congo red staining is negative.
Bella L. Liu +5 more
wiley +1 more source
Biology of Blood and Marrow Transplantation, 2018 The kidney is the most common organ affected by immunoglobulin light-chain (AL) amyloidosis and monoclonal immunoglobulin deposition disease (MIDD), often leading to end-stage renal disease (ESRD).
F. Batalini +9 more
semanticscholar +1 more source
A Case Report of a Special Type of Multiple Myeloma: Kappa Light Chain‐Only
Organ Medicine, Volume 3, Issue 2, Page 119-124, June 2026.This case illustrates the clinical course of a patient diagnosed with kappa light chain‐only multiple myeloma, a rare subtype of multiple myeloma. Of note, light chain multiple myeloma is characterized by rapid disease progression and severe target organ damage.
Yanhua Dai +8 more
wiley +1 more source
Púrpura: manifestação de amiloidose sistémica primária.
Acta Médica Portuguesa, 2009 Primary Systemic Amyloidosis (AL) is the most frequent form of systemic amyloidosis and its morbilility is associated with immunoglobulin light chains deposition in vital organs. The mucocutaneous manifestations occur in about 30-40% of the cases and are
Sara Lestre +4 more
doaj +1 more source
British Journal of Haematology, Volume 208, Issue 6, Page 2059-2068, June 2026.Renal dysfunction represents a possible underrecognized complication of symptomatic WM; this condition correlates with adverse global and disease‐specific clinical outcomes. Summary The prognostic significance of impaired renal function in Waldenström macroglobulinaemia (WM) remains poorly defined.
Nicolò Danesin +27 more
wiley +1 more source
A risk stratification for systemic immunoglobulin light‐chain amyloidosis with renal involvement
British Journal of Haematology, 2019 Renal involvement is found in about 70% of patients with systemic immunoglobulin light‐chain (AL) amyloidosis. However, there is no risk stratification system specialized for renal AL concerning patients’ survival. Galectin‐3 (Gal‐3) has been reported to
Ting Li +10 more
semanticscholar +1 more source
British Journal of Haematology, Volume 208, Issue 6, Page 2096-2103, June 2026.Summary Anti‐CD38 monoclonal antibodies dramatically improve the prognosis in immunoglobulin light‐chain (AL) amyloidosis, yet patients with end‐stage (Mayo 2004 IIIB) disease are typically excluded from prospective trials. To evaluate the daratumumab plus bortezomib and dexamethasone (Dara‐VD) regimen in Mayo 2004 stage III patients, we conducted a ...
Gao Xue‐min +7 more
wiley +1 more source